by Gary Wörtz, MD — In my opinion, compounded drops are the closest thing we have seen to the holy grail of postop pharmaceuticals in my career. Not only do compounded drops save patients money, the quality and convenience compared with both brand-name and generic formulations have piqued the interest of both providers and patients.
Dr. Steven R. Sarkisian, Jr., is the founder and CEO of Oklahoma Eye Surgeons, PLLC, as well as the former director of the glaucoma fellowship at the Dean McGee Eye Institute and clinical professor of Ophthalmology at the University of Oklahoma.
As Profits Rise, Ocular Science Promotes From Within
Ocular Science, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has promoted Eric Garner to Vice President of Marketing.
Ocular Science Taps Ophthalmology Medical Device Pro to Lead U.S. Sales
Ocular Science®, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has named Greg Anderson as its vice president of sales.
It is agreed that controlling inflammation and managing infection risk, via steroids and NSAIDS and antibiotics, respectively, are of monumental importance following cataract surgery.
ASCRS FDA Committee Member Speaks on Access to Compounded Drugs
ASCRS FDA committee member Damien Goldberg, MD, urges FDA to allow access to compounded drugs from traditional compounders without a patient-specific prescription.
